Dupixent Shows Positive Results for Children Under 12 with Eosinophilic Esophagitis in Phase 3 Trial
Dupilumab (Dupixent) is the primary medication to enhance indicators of eosinophilic esophagitis and help weight achieve in youngsters ages 1 to 11, for whom there are not any presently ...
Read more